Navigation Links
Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
Date:11/19/2007

Vaccines from Wyeth and GlaxoSmithKline Will Also Be Vying to Capture Shares of the Escalating Pneumococcal Vaccine Market, According to a New

Report from Decision Resources

WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most promising antibiotics in development for the treatment of community-acquired pneumonia are intravenous agents that will be used in the hospital setting, including Johnson & Johnson/Basilea's ceftobiprole and Forest's ceftaroline. The broad spectrum of these next- generation cephalosporins includes activity against methicillin-resistant Staphylococcus aureus.

The new Pharmacor report entitled Community-Acquired Pneumonia finds that in 2006 antibiotics generated more than $800 million while the pneumococcal vaccines garnered approximately $1.5 billion in sales in the major pharmaceutical markets. Decision Resources forecasts that the hospital segment of the community-acquired pneumonia market will experience considerable growth, driven by rising resistance rates that will encourage the uptake of novel products. However, growth in the outpatient market will be limited over the next decade given its maturity, increased availability of generic agents and the upcoming patent expiry of products such as Johnson & Johnson's Levaquin. The launch of vaccines in late-stage development from GlaxoSmithKline and Wyeth expand upon the serotype coverage of Wyeth's blockbuster vaccine, Prevnar, and will drive growth in the pneumococcal vaccine market.

"Community-acquired pneumonia is an important indication for antibiotic drug developers because it represents a sizeable inpatient population and can be a gateway indication to the large outpatient respiratory tract infections market," said Kaitlyn Sullivan, analyst at Decision Resources. "Drug resistance will lead to a shift in prescribing
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
5. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
6. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
7. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
8. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
9. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
10. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
11. Johnson & Johnson Announces Changes to Accelerate Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Pismo Beach, CA (PRWEB) June 03, 2015 ... passed a Senate Energy, Utilities and Communications Committee (11-0) and ... the DA CAP) and renewable energy. , The Committee Chairman ... amended to increase the CAP by 8,000 GWh and would ... the utility wait list. , This “Wait List” and ...
(Date:6/3/2015)... Milan, Tennessee (PRWEB) June 03, 2015 ... facility in Milan, Tennessee to support the RCBC Waste ... Energy is fourth generation in the family business, ... since 1908. His family added recycling to their ... waste and recycling services to the Fortune 500 companies ...
(Date:6/3/2015)... June 03, 2015 Marktech Optoelectronics is ... Photodiodes. Marktech APD’s have an internal gain mechanism, fast ... the near infrared region. These APD’s are recommended for ... is needed to overcome high pre-amp noise. In addition, ... and are ideal for extreme low-level light detection and ...
(Date:6/2/2015)... TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy ... whereby the institutional investors will have the option to ... up to $4.93M in near term funding, pending closing ... restructured terms and subject to certain market conditions, the ... in a larger influx of capital to fund the ...
Breaking Biology Technology:Bmark Energy Announces the Sign-up Deadline for Companies Interested in California’s Direct Access Program is June 12th, 2015 at 5:00pm. 2Marktech Introduces New Line of APDs 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3
... KANSAS CITY, Kansas , Aug. 5 Oncimmune® ... test that aids physicians in risk assessment and the early ... study that demonstrates the clinical validity of the test. The study ... Diagnosis " is now available on line at Annals of ...
... how a new type of experimental antibiotic can ... treatments [1]. The findings could ultimately help scientists ... responsible for many hospital and community-acquired infections. ... team of researchers from GlaxoSmithKline (GSK) captured a ...
... , Aug. 4 Forte, LLC, ... a web-based probate database and estate recovery application ... Probate Finder OnDemand provides access to a proprietary ... records, powerful matching algorithms that accurately match deceased ...
Cached Biology Technology:New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 3New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 4New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 5New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 6Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance 2Forte Launches Probate Finder OnDemand™ 2Forte Launches Probate Finder OnDemand™ 3
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... new, more effective and personalized cancer treatments, Horizon Discovery, ... Reserve University exclusive rights to a panel of new ... Zhenghe John Wang, assistant professor of genetics at the ... initially for 10 years and includes up-front fees and ...
... Institute at Virginia Tech have discovered how abscisic ... properties for the treatment of disease, helps fight ... published in the November 2010 Journal of ... for the development of treatments for inflammatory and ...
... Mich. The risk of esophageal cancer among patients ... as high as many may think, according to new ... considered a relative risk for developing esophageal adenocarcinoma, but ... M.D., M.Sc., an investigator with the Department of Veterans ...
Cached Biology News:Isogenic cell models for cancer research exclusively licensed to Horizon Discovery 2Researchers discover how natural drug fights inflammation 2Researchers discover how natural drug fights inflammation 3Esophageal cancer risk lower than expected for patients with GERD 2
A component of the Acridinium protein labeling kit....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
...
... calibration, and validation (MCV) plate ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...
Biology Products: